In January 2020, the FDA approbed avaprintinib for the treatment of metastatic gastrointestinal stromal tumors (GIST). This drug is approved for GIST tumors that harbor a specific mutation in FDGFRA gene. This gene mutation usually indicates a very resistant tumor to normal medications. Trials have shown a high response rate with almost 85% seeing tumor shrinkage. Side effects may include nausea, fatigue, memory loss and edema.